MDT

87.56

+0.44%↑

A

114.42

-2.15%↓

VEEV

160

-7.43%↓

HQY

83.34

+1.87%↑

TLRY

6.65

-1.92%↓

MDT

87.56

+0.44%↑

A

114.42

-2.15%↓

VEEV

160

-7.43%↓

HQY

83.34

+1.87%↑

TLRY

6.65

-1.92%↓

MDT

87.56

+0.44%↑

A

114.42

-2.15%↓

VEEV

160

-7.43%↓

HQY

83.34

+1.87%↑

TLRY

6.65

-1.92%↓

MDT

87.56

+0.44%↑

A

114.42

-2.15%↓

VEEV

160

-7.43%↓

HQY

83.34

+1.87%↑

TLRY

6.65

-1.92%↓

MDT

87.56

+0.44%↑

A

114.42

-2.15%↓

VEEV

160

-7.43%↓

HQY

83.34

+1.87%↑

TLRY

6.65

-1.92%↓

Search

Celldex Therapeutics Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

32.74 4.47

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

30.94

Max

32.81

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-14M

-81M

Pardavimai

75K

75K

Pelnas, tenkantis vienai akcijai

-1.22

Pelno marža

-108,422.667

Darbuotojai

198

EBITDA

-7.8M

-81M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+71.96% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-05-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

472M

2.1B

Ankstesnė atidarymo kaina

28.27

Ankstesnė uždarymo kaina

32.74

Naujienos nuotaikos

By Acuity

100%

0%

331 / 349 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

Celldex Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-08 20:44; UTC

Uždarbis

Costco Reports 11% Growth in March Sales

2026-04-08 23:51; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-08 23:51; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for Talks to End Iran War -- Market Talk

2026-04-08 23:36; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Gold Edges Lower on Likely Technical Correction -- Market Talk

2026-04-08 22:56; UTC

Rinkos pokalbiai

Ramelius Resources May Downgrade Cost Guidance This Month -- Market Talk

2026-04-08 22:45; UTC

Rinkos pokalbiai

Constellation Brands Points to Continuing Challenges Among Hispanic Consumers -- Market Talk

2026-04-08 22:17; UTC

Rinkos pokalbiai

Applied Digital Says Its Holding Out for Quality Customers -- Market Talk

2026-04-08 21:52; UTC

Svarbiausios naujienos

A Closer Look at Iran's 10 Demands -- and Which the U.S. Might Accept -- Update

2026-04-08 21:24; UTC

Uždarbis

FedEx Freight Aims for 12% Profit Growth. How That Compares to the Leader. -- Barrons.com

2026-04-08 21:01; UTC

Svarbiausios naujienos

Oil Prices Tumble Despite Conflicting Reports About the Strait of Hormuz -- Barrons.com

2026-04-08 20:50; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2026-04-08 20:43; UTC

Įsigijimai, susijungimai, perėmimai

Oracle Is Expressing No Opinion and Is Neutral as to Whether Stockholders Should Tender Their Shrs in Response to TRC's Offer >ORCL

2026-04-08 20:43; UTC

Įsigijimai, susijungimai, perėmimai

Oracle Does Not Endorse TRC's Mini-Tender Offer or the Offer Documentation >ORCL

2026-04-08 20:43; UTC

Įsigijimai, susijungimai, perėmimai

Oracle: Offer Represents Less Than 0.04% of Outstanding Common Stk >ORCL

2026-04-08 20:42; UTC

Įsigijimai, susijungimai, perėmimai

Oracle: TRC Offer Is to Purchase Up to 1M Shrs of Common Stk at $140.50/Shr in Cash >ORCL

2026-04-08 20:42; UTC

Įsigijimai, susijungimai, perėmimai

Oracle Received Notice of Unsolicited Mini-Tender Offer by TRC Dated March 24 >ORCL

2026-04-08 20:42; UTC

Įsigijimai, susijungimai, perėmimai

Oracle Responds to TRC Cap Mini-Tender Offer

2026-04-08 20:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-04-08 20:11; UTC

Įsigijimai, susijungimai, perėmimai

Intel Corp.: Repurchased 49% Equity Interest in JV Related to Intel's Fab 34 in Ireland >INTC

2026-04-08 20:11; UTC

Įsigijimai, susijungimai, perėmimai

Intel Corp.: $14.2B Repurchase Price Financed with Cash on Hand and a Bridge Loan of $6.5B >INTC

2026-04-08 20:11; UTC

Įsigijimai, susijungimai, perėmimai

Intel Corp.: Repurchased JV Stake From Apollo-Managed Funds and Affiliates >INTC

2026-04-08 19:44; UTC

Uždarbis

These Companies Pay 5% Dividend Yields, and They're Hiking Them Too -- Barrons.com

2026-04-08 19:16; UTC

Rinkos pokalbiai

Hogs Follow Cutout Prices Lower -- Market Talk

2026-04-08 19:02; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-04-08 19:02; UTC

Rinkos pokalbiai

Oil Futures Plunge as Cease-Fire Raises Hopes for Restored Supply -- Market Talk

2026-04-08 18:58; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Fall in Line With Slump in Oil -- Market Talk

2026-04-08 18:51; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-08 18:51; UTC

Rinkos pokalbiai

Levi Strauss CEO Says Expanded Offerings, DTC Focus Are Working -- Market Talk

2026-04-08 18:14; UTC

Svarbiausios naujienos

Fed Minutes Suggest a Lengthy Iran War Could Lead to Rate Hikes -- Barrons.com

2026-04-08 18:05; UTC

Svarbiausios naujienos

Oil Prices Continue to Tumble After Cease-Fire Despite Slow Reopening of Strait of Hormuz -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Celldex Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

71.96% į viršų

12 mėnesių prognozė

Vidutinis 53.91 USD  71.96%

Aukščiausias 90 USD

Žemiausias 24 USD

Remiantis 12 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Celldex Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

12 ratings

10

Pirkti

1

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

18.91 / 20.63Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat